Immune System Can be Coaxed into Selecting Key Antibodies to Fight HIV
Animal study shows ability to overcome a long-standing hurdle in HIV vaccine development
DURHAM, N.C. – Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.
The finding, led by a team of researchers at the Duke Human Vaccine Institute (DHVI) and Boston Children’s Hospital, publishes online Dec. 5.
“The reason we don’t have a vaccine is because the immune system doesn’t want to make the kind of antibodies that are needed to neutralize the virus,” said co-senior author Barton F. Haynes, M.D., director of the DHVI. “This study is proof of concept that we can engineer the immune system to create an environment where the right antibodies can be made.”
The researchers – including co-lead authors Kevin Saunders, Ph.D., and Kevin Wiehe, Ph.D. and Priyamvada Acharya, Ph.D., of the DHVI – built on years of successive studies that identified how and when broadly neutralizing antibodies (bnAbs) arise in people with HIV infections, and what prevents the antibodies from proliferating to negate the virus.
One problem lies in the immune system, which identifies some bnAbs as a danger and actively shuts down their production. Another problem is that the neutralizing antibodies require rare changes in their genetic make-up that are infrequently made during a crucial B-cell diversification process.
In the current study, the researchers traced those relevant mutations. Then they engineered an HIV protein, targeting a site called the V3 glycan region of the virus envelope, that preferentially bound to antibodies that have the unlikely but necessary mutations.
Using mouse models that express human neutralizing antibody precursors designed by co-senior author Frederick Alt, Ph.D., and co-first author Ming Tian of Boston Children’s Hospital, the Howard Hughes Medical Institute and Harvard Medical School, the researchers demonstrated that their immunogen could, indeed, coax a lineage of B-cells to undergo the improbable mutations that result in broadly neutralizing antibodies.
“Our ability to make mouse models that express human broadly neutralizing antibodies has provided powerful new model systems in which we can iteratively test experimental HIV vaccines”, said Alt, who directs Boston Children’s Program in Cellular and Molecular Medicine.
A second lineage of bnAbs -- binding to a different region of the virus’s outer envelope called the CD4 binding site that has long been a focus of HIV research -- also went through improbable mutations. After the researchers reconstructed this antibody’s history, they developed a second immunogen. Tested in non-human primates, it similarly selected for the necessary mutations, which led to the development of potent CD4 binding-site neutralizing antibodies.
“We have identified the mutations we need, which the immune system won’t easily make, and can select for them in a vaccine that targets that mutation,” Saunders said. “We have shown that we can overcome this major roadblock and can select for the right mutational changes in these bnAb precursors when they are starting to get better and better at neutralizing activity.”
The researchers noted that ongoing studies are needed to identify additional antibodies to target as they identify and build immunogens that would constitute a vaccine.
“Without proper antigen selection it will take multiple decades of vaccination to elicit effective antibodies,” Wiehe said. “We can accelerate this timeline by designing sequential immunogens that select for the required combination of functional antibody mutations.”
Haynes said the research demonstrates the intricacies of eliciting broadly neutralizing antibodies for HIV. And while an HIV vaccine still requires more work, the findings already have broader applications.
“This strategy of selecting specific antibody nucleotides by immunogen design can be applied to other infections for which vaccine development has been difficult,” Haynes said.
Additionally, he said, the insights gained from the HIV research have direct implications for cancer immunotherapies and treatments for autoimmune disorders. Both require strategies that precisely turn the immune system on or off without triggering a harmful cascade of unintended consequences.
“We have learned much about the rules of how the B-cell arm of the immune system is controlled and how to manipulate the immune system in a way that it makes the desired type of antibodies,” Haynes said.
In addition to Haynes, Saunders, Wiehe and Acharya, study authors from Duke include David Montefiori, Todd Bradley, S. Munir Alam, Richard Scearce, Laura Sutherland, Rory Henderson, Haiyan Chen, Xiaozhi Lu, Nelson R. Wu, Brian Watts, Chuancang Jiang, David Easterhoff, Amanda Eaton, Jinsong Zhang, Wes Rountree, Laurent Verkoczy, Robert J. Edwards, Derek W. Cain and Mattia Bonsignori.
Along with Alt and Tian, study authors from Boston Children’s Hospital, Harvard Medical School and the Howard Hughes Medical Institute include Hwei-Ling Cheng, Kelly McGovern, Peyton Waddicor and Aimee Williams.
Additional authors include Eden P. Go and Heather R. Desaire from the University of Kansas, Lawrence; Allen Hsu and Mario Borgnia from the National Institute of Environmental Health Sciences; Mark Tomai of the 3M company; and Mark G. Lewis of Bioqual.
The study received funding from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (R01-AI120801, UM1-AI100645, UM1-AI144371, R01-AI125093), and from the Duke Translational Health Initiative.